Table 2.

Base-Case Costs and Outcomes of Unfractionated Heparin (UH), Low-Molecular-Weight Heparin (LMWH), and Selective UH/LMWH in the Treatment of Deep Venous Thrombosis

	Strategy
Measure of Effectiveness	UH for all	LMWH for all	Selective UH/LMWH*
Estimates per 1,000 patients treated, $
Cost, total	3,203,329	2,892,564	2,795,742
During index case	3,040,187	2,775,095	2,662,779
During follow-up (3 mo)	163,142	117,469	132,963
Recurrent thrombosis, n	61.43	44.74	54.76
Mortality, n	6.2	4.2	5.4
During index case	0.8	0.3	0.6
During follow-up (3 mo)	5.4	3.9	4.8
Cost-effectiveness as compared to UH for all†
Recurrent thrombosis	—	Dominant	Dominant
Mortality	—	Dominant	Dominant

^*UH if hospitalized; LMWH if home treatment.

^†A strategy is dominant if it costs less and has better outcomes.